Product Description

🔹 Product Overview
CRESP 200 mcg Injection contains Darbepoetin Alfa 200 mcg, a long-acting erythropoiesis-stimulating agent (ESA). It is a prescription medicine used to treat certain types of anemia, particularly anemia associated with chronic kidney disease (CKD) and anemia associated with chemotherapy in eligible adult cancer patients.
Darbepoetin alfa works by stimulating the bone marrow to produce more red blood cells, helping improve hemoglobin levels and reduce symptoms associated with anemia.

🔹 Key Uses
Treatment of symptomatic anemia associated with chronic kidney disease
Treatment of anemia in appropriate adult cancer patients receiving chemotherapy
Used in patients with CKD who are receiving dialysis or are not receiving dialysis
Helps stimulate red blood cell production
Helps manage anemia-related symptoms such as tiredness and weakness when anemia is appropriately treated

🔹 Composition
Active ingredient: Darbepoetin Alfa
Strength: 200 mcg
Drug class: Erythropoiesis-stimulating agent (ESA)
Therapeutic category: Hematology / blood-related medicine
Dosage form: Solution for injection
Presentation: Prefilled syringe or single-dose vial, depending on the product presentation

🔹 How It Works
Darbepoetin alfa is a synthetic form of a protein that acts similarly to naturally occurring erythropoietin. It stimulates receptors in the bone marrow, encouraging the production of red blood cells.
By increasing red blood-cell production, darbepoetin alfa can help raise hemoglobin levels and improve anemia associated with conditions such as chronic kidney disease and chemotherapy.

🔹 Key Benefits
Helps increase red blood cell production
Helps improve hemoglobin levels in appropriate patients
Helps manage symptomatic anemia associated with chronic kidney disease
Provides a treatment option for chemotherapy-associated anemia in eligible adult cancer patients
Has a longer duration of action than conventional recombinant human erythropoietin, allowing less frequent administration in appropriate treatment schedules

🔹 Dosage and Administration
CRESP 200 mcg must be used only under the supervision of a qualified healthcare professional. The appropriate dose and administration frequency depend on the underlying cause of anemia, hemoglobin level, kidney function, chemotherapy regimen, and individual patient response.
Darbepoetin alfa may be administered by subcutaneous injection or, in certain CKD patients, by intravenous administration according to the prescribed treatment plan. The 200 mcg strength is not a universal dose and should not be administered without a physician's specific instructions.
Regular hemoglobin monitoring is required, and the dose may need to be adjusted according to the patient's response.

🔹 Possible Side Effects
Possible side effects may include:
Increased blood pressure
Injection-site reactions
Headache
Muscle or joint pain
Fatigue
Swelling or fluid retention
Nausea
Cough or respiratory symptoms
More serious complications, including blood clots and cardiovascular events, can occur, particularly when hemoglobin is raised excessively or treatment is not appropriately monitored.

🔹 Precautions
CRESP should be used under close medical supervision.
Inform your doctor if you have:
Uncontrolled high blood pressure
Heart disease
A history of stroke or blood clots
Kidney disease
Seizure disorders
A history of severe allergic reactions to erythropoietin products
Any other significant medical condition